Purdue Pharma

Harm Reduction Therapeutics is a nonprofit pharmaceutical company advancing harm reduction therapies to promote public health.

SpineThera develops novel, sustained-release, injectable drugs to treat pain; offering patients and physicians alternatives that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. It was founded in 2012 and is headquartered in Plymouth, Minnesota.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Infinity Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative treatments for various cancers. The company's lead candidate, eganelisib, is an oral immuno-oncology therapy that aims to reprogram macrophages to counteract immune suppression in cancer. Infinity is conducting multiple clinical trials to evaluate eganelisib in combination with established therapies, including global studies such as MARIO-275, which tests eganelisib alongside Opdivo® in patients with urothelial cancer, and MARIO-3, which explores combinations with Tecentriq® and Abraxane® in triple-negative breast cancer as well as with Tecentriq and Avastin® in renal cell carcinoma. Additionally, Infinity is collaborating with Arcus Biosciences to test a novel regimen that combines eganelisib with etrumadenant and Doxil® for advanced triple-negative breast cancer patients. The company's research also encompasses treatments for hematologic malignancies and solid tumors, reflecting its commitment to addressing various oncological challenges.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Infinity Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative treatments for various cancers. The company's lead candidate, eganelisib, is an oral immuno-oncology therapy that aims to reprogram macrophages to counteract immune suppression in cancer. Infinity is conducting multiple clinical trials to evaluate eganelisib in combination with established therapies, including global studies such as MARIO-275, which tests eganelisib alongside Opdivo® in patients with urothelial cancer, and MARIO-3, which explores combinations with Tecentriq® and Abraxane® in triple-negative breast cancer as well as with Tecentriq and Avastin® in renal cell carcinoma. Additionally, Infinity is collaborating with Arcus Biosciences to test a novel regimen that combines eganelisib with etrumadenant and Doxil® for advanced triple-negative breast cancer patients. The company's research also encompasses treatments for hematologic malignancies and solid tumors, reflecting its commitment to addressing various oncological challenges.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.